CORONA Remedies Q1 Results FY27: Date, Revenue Estimates, Key Catalysts and Share Price Target

July 3, 2026
Posted by: Kunal Singla
Category: News

CORONA Remedies CMP Rs.2,041. Q1 FY27E revenue Rs.392-451 Cr. PAT estimate Rs.58-74 Cr. 12-month target Rs.2,368-2,634.

CORONA Remedies Q1 Results FY27 is coming into focus as investors position ahead of the July-August 2026 results season, with CORONA Remedies shares trading at Rs.2,041 against a market capitalisation of Rs.12,287 Cr and a price-to-earnings multiple of 66.4. As an industrials and capital goods name on the NSE and BSE, CORONA Remedies enters the CORONA Remedies Q1 Results FY27 print with the Street watching revenue momentum, margin trajectory and management commentary on FY27 guidance.

This CORONA Remedies Q1 Results FY27 preview is built on a trailing-growth framework applied to the company’s Q1 FY26 base of Rs.349 Cr revenue and Rs.46 Cr net profit, using the most recent year-on-year growth signal from Q4 FY26. This Q1 prediction is a Uniresearch trailing-growth projection, not a formal analyst estimate, and should be read alongside the company’s own guidance once released.

Get Free Investment Predictions and CORONA Remedies Research at Univest

Table of Contents

About CORONA Remedies

CORONA Remedies (NSE: CORONA) operates in the industrials and capital goods space and is tracked on Univest under its NSE and BSE listings. Ahead of the CORONA Remedies Q1 Results FY27 print, the company’s Q4 FY26 base shows revenue of Rs.357 Cr and net profit of Rs.45 Cr, forming the base against which the CORONA Remedies Q1 Results FY27 estimates in this article are built. This CORONA Remedies Q1 Results FY27 snapshot is intended as a starting point for research, not a substitute for the company’s own disclosures.

CORONA Remedies Q1 FY27 Estimates

Metric	Q1 FY27E (Range)	Q1 FY26 Actual	YoY Growth
Revenue (Rs. Cr)	392-451	349	+21.0%
Net Profit / PAT (Rs. Cr)	58-74	46	+43.7%
Results Date	July-August 2026 (indicative)
12-Month Target (Uniresearch Estimate)	Rs.2,368-2,634

Univest, a SEBI-Registered Investment Advisor, Tracks CORONA Remedies Ahead of Q1 FY27 Results

Key Catalysts to Watch

1. Order Book Execution

Healthy order book execution translating into revenue recognition for the quarter is one of the primary variables that analysts are tracking ahead of CORONA Remedies’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the CORONA Remedies share price target or faces renewed pressure.

2. Capex Revival in User Industries

Capex revival in core user industries supporting fresh order inflows is one of the primary variables that analysts are tracking ahead of CORONA Remedies’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the CORONA Remedies share price target or faces renewed pressure.

3. Operating Leverage

Operating leverage on higher volumes aiding margin expansion versus last year is one of the primary variables that analysts are tracking ahead of CORONA Remedies’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the CORONA Remedies share price target or faces renewed pressure.

Download the Univest iOS App or Univest Android App to track CORONA Remedies’s live price and Q1 FY27 result updates.

Key Risks to the CORONA Remedies Q1 Results FY27 Outlook

Order execution delays pushing revenue recognition to later quarters.
Raw material and input cost inflation pressuring margins.
Slower capex recovery in key end-user industries affecting order inflows.

Q4 FY26 Performance Context for the CORONA Remedies Q1 Results FY27 Print

CORONA Remedies closed Q4 FY26 with revenue of Rs.357 Cr and net profit of Rs.45 Cr, a year-on-year revenue change of +21.0% and PAT change of +43.7%. This base underpins the CORONA Remedies Q1 Results FY27 projection used in this preview and should be read alongside the company’s own CORONA Remedies Q1 Results FY27 commentary once reported.

Technical Analysis Ahead of CORONA Remedies Q1 Results FY27

CORONA Remedies shares last traded at Rs.2,041. For the current 52-week high and low, support and resistance levels, investors should check the live chart on the Univest app or the NSE website, since these levels move intraday and are not reproduced here to avoid stale data.

Share Price Target Based on the CORONA Remedies Q1 Results FY27 Outlook

3-6 Month Target

Over a 3-6 month horizon, the CORONA Remedies Q1 Results FY27 trailing-growth framework points to a range of Rs.2,110-2,273 for CORONA Remedies, contingent on the CORONA Remedies Q1 Results FY27 print matching or beating the trailing growth trend.

12-Month Target

The 12-month target (Uniresearch estimate) tied to this CORONA Remedies Q1 Results FY27 view for CORONA Remedies works out to Rs.2,368-2,634, built on the same trailing revenue growth trend and current valuation multiple. Tracking with a constructive bias is how Univest research categorises the stock heading into CORONA Remedies Q1 Results FY27, not a formal Buy or Sell call.

FY27-28 Outlook

Looking out to FY27-28, a sustained continuation of the growth trajectory implied by this CORONA Remedies Q1 Results FY27 analysis would put CORONA Remedies in a Rs.2,667-3,034 range, though this is sensitive to sector-wide demand, cost trends and any change in the company’s competitive position.

What to Watch in the CORONA Remedies Q1 Results FY27 Print

Revenue and PAT versus the CORONA Remedies Q1 Results FY27 estimate range in this preview.
Management commentary on FY27 growth guidance and margin trajectory relevant to the CORONA Remedies Q1 Results FY27 narrative.
Healthy order book execution translating into revenue recognition for the quarter
Order execution delays pushing revenue recognition to later quarters

Conclusion on CORONA Remedies Q1 Results FY27

CORONA Remedies enters the Q1 FY27 results season trading at Rs.2,041, with the 12-month Uniresearch target range of Rs.2,368-2,634 reflecting a tracking with a constructive bias stance. Investors tracking the CORONA Remedies Q1 Results FY27 print should watch the catalysts and risks above and consult a SEBI-registered advisor before making investment decisions around the results.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs on CORONA Remedies Q1 Results FY27

When are CORONA Remedies Q1 FY27 results expected?

Ans. CORONA Remedies’s Q1 FY27 results are expected in the July-August 2026 window, in line with the broader NSE and BSE results season for the quarter ending June 2026.

What is the CORONA Remedies Q1 FY27 revenue estimate?

Ans. The Uniresearch trailing-growth estimate for CORONA Remedies’s Q1 FY27 revenue is Rs.392-451 Cr, based on the Q1 FY26 base of Rs.349 Cr.

What is the CORONA Remedies share price target?

Ans. The 12-month Uniresearch estimate for CORONA Remedies share price target is Rs.2,368-2,634, based on trailing growth and current valuation multiples.

Is CORONA Remedies a good buy before Q1 FY27 results?

Ans. CORONA Remedies is tracking with a constructive bias heading into Q1 FY27 results. Investors should weigh the catalysts and risks in this article and consult a SEBI-registered advisor before investing.

What should investors watch in CORONA Remedies’s Q1 FY27 results?

Ans. Key items include revenue and PAT versus estimates, management commentary on FY27 guidance, and healthy order book execution translating into revenue recognition for the quarter.

Where can I track CORONA Remedies share price live?

Ans. CORONA Remedies share price can be tracked live on the Univest app and website, along with research updates from SEBI-registered analysts.

Author: Kunal Singla

Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.